Marc Fischer

Marc Fischer

Auto-generated profile, based on publicly available information

Marc Fischer

Arboviral Diseases Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2008 in Virology Journal
Verified
Journal Article
Open access
PDF file
FJFidan Jmor
Fidan Jmor
HEHedley C. A. Emsley
Hedley C. A. Emsley
MFMarc Fischer
Marc Fischer
TSTom Solomon
Tom Solomon
PLPenny Lewthwaite
Penny Lewthwaite
As part of efforts to control Japanese encephalitis (JE), the World Health Organization is producing a set of standards for JE surveillance, which require the identification of patients with acute encephalitis syndrome (AES). This review aims to provide information to determine what minimum annual incidence of AES should be reported to show that the surveillance programme is active.

2 October 2019 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
LALaura Adams
Laura Adams
SMStacey W. Martin
Stacey W. Martin
NLNicole P. Lindsey
Nicole P. Lindsey
JLJennifer A. Lehman
Jennifer A. Lehman
ARAidsa Rivera
Aidsa Rivera
MFMarc Fischer
Marc Fischer
Dengue, chikungunya, and Zika viruses, primarily transmitted by Aedes species mosquitoes, have caused large outbreaks in the Americas, leading to travel-associated cases and local mosquito-borne transmission in the United States. We describe the epidemiology of dengue, chikungunya, and noncongenital Zika virus disease cases reported from U.S. states and territories in 2017, including 971 dengue cases, 195 chikungunya cases, and 1,118 Zika virus disease cases. Cases of all three diseases reported from the territories were reported as resulting from local mosquito-borne transmission. Cases reported from the states were primarily among travelers, with only seven locally acquired mosquito-transmitted Zika virus disease cases reported from Texas (n = 5) and Florida (n = 2). In the territories, most dengue cases (n = 508, 98%) were reported from American Samoa, whereas the majority of chikungunya (n = 39, 100%) and Zika virus disease (n = 620, 93%) cases were reported from Puerto Rico. Temporally, the highest number of Zika virus disease cases occurred at the beginning of the year, followed by a sharp decline, mirroring decreasing case numbers across the Americas following large outbreaks in 2015 and 2016. Dengue and chikungunya cases followed a more seasonal pattern, with higher case numbers from July through September. Travelers to the United States and residents of areas with active virus transmission should be informed of both the ongoing risk from dengue, chikungunya, and Zika virus disease and personal protective measures to lower their risk of mosquito bites and to help prevent the spread of these diseases.

11 April 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJ Erin Staples
J Erin Staples
DPDaniel M Pastula
Daniel M Pastula
APAmanda J Panella
Amanda J Panella
IRIngrid B Rabe
Ingrid B Rabe
OKOlga I Kosoy
Olga I Kosoy
MFMarc Fischer
Marc Fischer
Heartland virus (HRTV) was first described as a human pathogen in 2012. From 2013–2017, CDC implemented a national protocol to evaluate patients for HRTV disease, better define its geographic distribution, epidemiology and clinical characteristics, and develop diagnostic assays for this novel virus. Individuals aged ≥12 years, whose clinicians contacted state health departments or CDC about testing for HRTV infections, were screened for recent onset of fever with leukopenia and thrombocytopenia. A questionnaire was administered to collect data on demographics, risk factors, and signs and symptoms; blood samples were tested for the presence of HRTV RNA and neutralizing antibodies. Of 85 individuals enrolled and tested, 16 (19%) had evidence of acute HRTV infection, 1 (1%) had past infection, and 68 (80%) had no infection. Patients with acute HRTV disease were residents of 7 states, 12 (75%) were male, and median age was 71 years (range: 43–80 years). Illness onset occurred from April to September. The majority reported fatigue, anorexia, nausea, headache, confusion, arthralgia, or myalgia. Fourteen (88%) cases were hospitalized; 2 (13%) died. Fourteen (88%) participants reported an attached tick in the 2 weeks prior to illness onset. HRTV-infected individuals were significantly older (P<0.001) and more likely to report an attached tick (P=0.03) than uninfected individuals. Healthcare providers should consider HRTV disease testing in patients with an acute febrile illness with either leukopenia or thrombocytopenia not explained by another condition or were suspected to have a tickborne disease but did not improve following appropriate treatment.

20 March 2012 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SBSteven A. Baty
Steven A. Baty
KGKatherine Gibney
Katherine Gibney
JSJ. Erin Staples
J. Erin Staples
APAndrean Bunko Patterson
Andrean Bunko Patterson
CLCraig Levy
Craig Levy
MFMarc Fischer
Marc Fischer

1 October 2014 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
BDBhushan R. Deshpande
Bhushan R. Deshpande
SRSowmya R. Rao
Sowmya R. Rao
EJEmily S. Jentes
Emily S. Jentes
SHSusan L. Hills
Susan L. Hills
MFMarc Fischer
Marc Fischer
RLRegina C. LaRocque
Regina C. LaRocque
Few data regarding the use of Japanese encephalitis (JE) vaccine in clinical practice are available. We identified 711 travelers at higher risk and 7,578 travelers at lower risk for JE who were seen at US Global TravEpiNet sites from September of 2009 to August of 2012. Higher-risk travelers were younger than lower-risk travelers (median age = 29 years versus 40 years, P < 0.001). Over 70% of higher-risk travelers neither received JE vaccine during the clinic visit nor had been previously vaccinated. In the majority of these instances, clinicians determined that the JE vaccine was not indicated for the higher-risk traveler, which contradicts current recommendations of the Advisory Committee on Immunization Practices. Better understanding is needed of the clinical decision-making regarding JE vaccine in US travel medicine practices.

1 May 2017 in Vaccine
Verified
Journal Article
Open access
MSManjunath B. Shankar
Manjunath B. Shankar
JSJ. Erin Staples
J. Erin Staples
MMMartin I. Meltzer
Martin I. Meltzer
MFMarc Fischer
Marc Fischer
West Nile virus (WNV) is the leading cause of domestically-acquired arboviral disease in the United States. Several WNV vaccines are in various stages of development. We estimate the cost-effectiveness of WNV vaccination programs targeting groups at increased risk for severe WNV disease. We used a mathematical model to estimate costs and health outcomes of vaccination with WNV vaccine compared to no vaccination among seven cohorts, spaced at 10year intervals from ages 10 to 70years, each followed until 90-years-old. U.S. surveillance data were used to estimate WNV neuroinvasive disease incidence. Data for WNV seroprevalence, acute and long-term care costs of WNV disease patients, quality-adjusted life-years (QALYs), and vaccine characteristics were obtained from published reports. We assumed vaccine efficacy to either last lifelong or for 10years with booster doses given every 10years. There was a statistically significant difference in cost-effectiveness ratios across cohorts in both models and all outcomes assessed (Kruskal-Wallis test p<0.0001). The 60-year-cohort had a mean cost per neuroinvasive disease case prevented of $664,000 and disability averted of $1,421,000 in lifelong model and $882,000 and $1,887,000, respectively in 10-year immunity model; these costs were statistically significantly lower than costs for other cohorts (p<0.0001). Vaccinating 70-year-olds had the lowest cost per death averted in both models at around $4.7 million (95%CI $2-$8 million). Cost per disease case averted was lowest among 40- and 50-year-old cohorts and cost per QALY saved lowest among 60-year cohorts in lifelong immunity model. The models were most sensitive to disease incidence, vaccine cost, and proportion of persons developing disease among infected. Age-based WNV vaccination program targeting those at higher risk for severe disease is more cost-effective than universal vaccination. Annual variation in WNV disease incidence, QALY weights, and vaccine costs impact the cost effectiveness ratios.